Rasburicase for Hyperuricemia

NCT00290992 | Completed Phase 2

• 1 other identifier: ACT5080
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration. Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP antibodies, and pharmacokinetic parameters.

Conditions

Nutritional and Metabolic Diseases

Keywords

urate oxidase, hyperuricemia, lymphoma, leukemia

Outcome Measures

Primary Outcomes (1)

• Patients with a plasma uric acid level decreased to the endpoint by 48 hr after the start of first drug infusion and lasting until 24 hr after the start of final (Day 5) drug infusion.

Secondary Outcomes (4)

• Safety will be assessed on clinical observation, laboratory test, vital sign (blood pressure, pulse rate and body temperature), and the occurrence of adverse events.

• G6PD activity will be measured in only patients who demonstrate hemolysis.

• Anti-SR29142 antibody and Anti-SCP antibody will be measured.

• PK parameters.

Interventions

rasburicase (SR29142) DRUG

Eligibility Criteria

• Age: Up to 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• \<18 years of age
• Patient with newly diagnosed hematological malignancies presenting with hyperuricemia:
• Uric acid \> 7.5 mg/dL in patients ≥ 13 years old- Uric acid \> 6.5mg/dL in patients \<13 years old
• Or, patient with newly diagnosed hematological malignancies presenting with high tumor burden defined:
• Non-Hodgkin's lymphoma, Stage IV regardless of uric acid level,
• Non-Hodgkin's Lymphomas stage III regardless of uric acid level with one of the following:
• At least one lymph node or mass \>5 cm in diameter
• LDH ≥ 3 x ULN (IU/L): Judging according to modified Murphy's classification
• Acute leukemia with white blood cell count (WBC) ≥ 50,000/mm3 or LDH ≥ 3 x ULN (IU/L) regardless of uric acid level. etc.

You may not qualify if:

• Patients who have received or are scheduled to receive other investigational drugs in 30 days prior to the start of SR29142 administration or during the trial period.
• Low birth weight infant (\<2500g) or gestational age \<37 weeks
• Patients who have received or are scheduled allopurinol within 72 hrs prior to the first dose of SR29142 or during the trial period.
• Known history of severe allergic reaction and/or severe asthma.
• Known history or family history of glucose-6-phosphate dehydrogenase deficiency.
• Known history of hemolysis and methemoglobinemia.
• Severe disorders of liver or kidney. ALT (GPT) \> 5.0 x ULN, Total Bilirubin \> 3.0 x ULN, Creatinine \> 3.0 x ULN
• Uncontrollable infections (including viral infections).
• Known positive tests for HBs antigen, HCV antibodies, or HIV-1, 2 antibodies. etc.

Sponsors & Collaborators

• Sanofi: lead

Study Sites (1)

Sanofi-Aventis

Tokyo, Japan

Location

MeSH Terms

Conditions

Nutritional and Metabolic Diseases; Hyperuricemia; Lymphoma; Leukemia

Interventions

rasburicase; Urate Oxidase

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Hematologic Diseases

Intervention Hierarchy (Ancestors)

Oxidoreductases; Enzymes; Enzymes and Coenzymes

Study Officials

• Keiji OHNO

  Sanofi

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: February 10, 2006
• First Posted: February 13, 2006
• Study Start: June 1, 2005
• Primary Completion: April 1, 2006
• Study Completion: April 1, 2006
• Last Updated: March 30, 2009

Record last verified: 2009-03

Locations

JP (1)